Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Sheyu Li, Per Olav Vandvik, Lyubov Lytvyn, et al.
BMJ (2021), pp. n1091-n1091
Open Access | Times Cited: 90

Showing 26-50 of 90 citing articles:

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
Yuting Ma, Guangdong Zhang, Zenggguang Kuang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Qualitative study of guideline panelists: innovative surveys provided valuable insights regarding patient values and preferences
Linan Zeng, Shelly‐Anne Li, Mengting Yang, et al.
Journal of Clinical Epidemiology (2023) Vol. 161, pp. 173-180
Open Access | Times Cited: 10
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
Jiani Zhong, Hang Chen, Qiming Liu, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 14, Iss. 5, pp. 100917-100917
Open Access | Times Cited: 9
Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial
Lixin Guo, L. S. Wang, D. Tian, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 11, pp. 2351-2366
Open Access | Times Cited: 3
CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
Cankun Zheng, Wanling Xuan, Zhenhuan Chen, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 14
Effect and pharmacological mechanism of Salvia miltiorrhiza and its characteristic extracts on diabetic nephropathy
Lu-Qi Cai, Yu Chen, Huizhong Xue, et al.
Journal of Ethnopharmacology (2023) Vol. 319, pp. 117354-117354
Closed Access | Times Cited: 8
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
Chunyan Liu, Tianqiang Wu, Na Ren
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 2
Physicians found an interactive tool displaying structured evidence summaries for multiple comparisons understandable and useful: a qualitative user testing study
Per Olav Løvsletten, Birk Stokke Hunskaar, Anja Fog Heen, et al.
Journal of Clinical Epidemiology (2024) Vol. 172, pp. 111399-111399
Open Access | Times Cited: 2
Enrollment of Black, Indigenous and People of Color (BIPOC) and female participants in the US diabetes trials spanning 2000 to 2020: A chronological survey
Jingyi Zhang, Miaoguan Peng, Jianfeng Li, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 7, pp. 103074-103074
Closed Access | Times Cited: 2
Radix Astragali and Its Representative Extracts for Diabetic Nephropathy: Efficacy and Molecular Mechanism
Hui‐zhong Xue, Yu Chen, Shi-Dong Wang, et al.
Journal of Diabetes Research (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 2
Chinese expert consensus on the management of hypertension in adults with type 2 diabetes
Xiaohui Pan, Hongbo He, Yuqian Bao, et al.
Journal of Evidence-Based Medicine (2024) Vol. 17, Iss. 4, pp. 851-864
Open Access | Times Cited: 2
Worldwide burden attributable to diet high in red meat from 1990 to 2019
Dan Liu, Qingyang Shi, Gaiping Cheng, et al.
Archives of Medical Science (2022)
Open Access | Times Cited: 12
Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications
Lidia Staszewsky, Marta Baviera, Mauro Tettamanti, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 2, pp. e002708-e002708
Open Access | Times Cited: 11
Association of the triglyceride‐glucose index with subclinical left ventricular dysfunction in type 2 diabetes mellitus patients: A retrospective cross‐sectional study
Qichao Sun, Jie Liu, Ran Meng, et al.
Journal of Diabetes Investigation (2023) Vol. 14, Iss. 8, pp. 953-960
Open Access | Times Cited: 6
Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes
Chelsy L. Cliff, Bethany M. Williams, Christos Chadjichristos, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 600-600
Open Access | Times Cited: 10
Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR
Adam Arshad, Nadia Sarween, Adnan Sharif
Kidney International Reports (2021) Vol. 6, Iss. 9, pp. 2415-2424
Open Access | Times Cited: 13
Comparison of statistical methods for integrating real‐world evidence in a rare events meta‐analysis of randomized controlled trials
Minghong Yao, Yuning Wang, Yan Ren, et al.
Research Synthesis Methods (2023) Vol. 14, Iss. 5, pp. 689-706
Open Access | Times Cited: 5
Cardiovascular benefit of SGLT2 inhibitors
Reza Mohebi, James L. Januzzi
Critical Reviews in Clinical Laboratory Sciences (2021) Vol. 59, Iss. 3, pp. 142-155
Closed Access | Times Cited: 11
Metformin monotherapy versus predominantly older non‐metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management
Mingyang Sun, Zhongyuan Lu, Wan‐Ming Chen, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 3914-3925
Closed Access | Times Cited: 1
Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
Kyriakos Kintzoglanakis, Christos Diamantis, Anargiros Mariolis, et al.
Diabetes and Vascular Disease Research (2024) Vol. 21, Iss. 4
Open Access | Times Cited: 1
Commentary: Shared decision making for weight‐lowering medications in China
Qingyi Jia, Sheyu Li
Clinical and Translational Medicine (2024) Vol. 14, Iss. 11
Open Access | Times Cited: 1
Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials
Huilin Tang, Bingyu Zhang, Yiwen Lu, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
Emanuela Orsi, Anna Solini, Enzo Bonora, et al.
Acta Diabetologica (2022) Vol. 59, Iss. 10, pp. 1369-1381
Open Access | Times Cited: 7

Scroll to top